■ Bibliografia
  1. Wang C, Valera L, Jia L, Kirk MJ, Gao M, Fridell RA. In vitro activityof daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother 2013;57:611–613.
  2. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-21.
  3. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:714–25.
  4. Nelson DR, Cooper JN, Lalezari JP et al, All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61:1127-1135.
  5. Leroy V, Angus PW, Bronowicki JP, et al. All-Oral treatment with daclatasvir (DCV) plus sofosbuvir (SOF) plus ribavirin (RBV) for 12 or 16 weeks in HCV genotype (GT) 3-infected patients with advanced fibrosis or cirrhosis: The ALLY-3+ Phase 3 Study. Hepatology 2016. doi:10.1002/hep.28473 [Epub ahead of print]
  6. Kowdley KV, Angus P, Bernstein D, et al. All-Oral Treatment with Daclatasvir Plus Sofosbuvir ± Ribavirin in HCV Genotype 3-Infected Patients With Advanced Fibrosis or Cirrhosis: An Analysis of ALLY-3 and ALLY-3+. The International Liver Congress™ 2016
    The 51st Annual Meeting of the European Association for the Study of the Liver
    Barcelona, Spain, April 13–17, 2016 Poster SAT-199
  7. Hézode C, Dore GJ, Pianko S, et al. Daclatasvir Plus Sofosbuvir Plus Ribavirin for
    12 or 16 Weeks in Treatment-Experienced Patients with HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis. The International Liver Congress™ 2016
    The 51st Annual Meeting of the European Association for the Study of the Liver
    Barcelona, Spain, April 13–17, 2016. Poster SAT-129
  8. Poordad F, et al. Hepatology 2016; doi: 10.1002/hep.28446.
  9. Poordad F, Fontana RJ, Schiff ER, et al. Factors Impacting SVR12 for Patients With Advanced Cirrhosis Receiving Daclatasvir and Sofosbuvir With Ribavirin in the ALLY-1 Study. The International Liver Congress™ 2016 The 51st Annual Meeting of the European Association for the Study of the Liver Barcelona, Spain, April 13–17, 2016. Poster SAT-158.
  10. Hézode C, Abergel A, Chas J, Sustained Virologic Response to Daclatasvir and Sofosbuvir, With or Without Ribavirin, Among Patients in the French Daclatasvir ATU programme Infected With HCV Genotypes 4, 5 and 6. The International Liver Congress™ 2016
    The 51st Annual Meeting of the European Association for the Study of the Liver
    Barcelona, Spain, April 13–17, 2016. Poster SAT-131
  11. Leroy V, Hézode C, Métivier S et al. Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With HCV Infection and Decompensated Cirrhosis: Interim Analysis of a French Multicentre Compassionate Use Programme. The International Liver Congress™ 2016
    The 51st Annual Meeting of the European Association for the Study of the Liver
    Barcelona, Spain, April 13–17, 2016. Poster SAT-282
  12. Petersen J, Welzel TM, Herzer K, et al. Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Chronic HCV Infection in Patients With Decompensated Cirrhosis: Results of a European Multicentre Compassionate Use Programme. The International Liver Congress™ 2016 The 51st Annual Meeting of the European Association for the Study of the Liver Barcelona, Spain, April 13–17, 2016. Poster SAT-184
  13. Welzel TM, Petersen J, Herzer K, et al. Daclatasvir Plus Sofosbuvir With or Without Ribavirin for Treatment of Chronic HCV Infection in Patients With Advanced Liver Disease: Results of a European Compassionate Use Programme. The International Liver Congress™ 2016 The 51st Annual Meeting of the European Association for the Study of the Liver Barcelona, Spain, April 13–17, 2016. Poster SAT-275
  14. Brown Jr RS, Fried MW, Reddy KR, et al. Daclatasvir and Sofosbuvir Therapy for Patients with Decompensated Cirrhosis or Post Liver Transplant HCV Recurrence and Advanced Fibrosis or Cirrhosis: United States Multicentre Treatment Protocol. The International Liver Congress™ 2016 The 51st Annual Meeting of the European Association for the Study of the Liver Barcelona, Spain, April 13–17, 2016. Poster SAT-251
  15. Weis N, Young J, Hofer H, et al. Effectiveness of Daclatasvir-based Therapy in Patients With Chronic Hepatitis C in Europe: Experience From the Named Patient Program. The International Liver Congress™ 2016 The 51st Annual Meeting of the European Association for the Study of the Liver Barcelona, Spain, April 13–17, 2016. Poster SAT-224.
  16. Cornberg M, Buggisch P, Schober A et al. Treatment of patients with HCV genotype infection in the era of direct acting antivirals (DAA): Data from the german hepatitis C-registry (DHC-R). The International Liver Congress™ 2016 The 51st Annual Meeting of the European Association for the Study of the Liver Barcelona, Spain, April 13–17, 2016. Poster SAT-208
© Effetti srl